mitochondrial ribosomal protein L30 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored MRPL30P1 profile across patient tissues and cancer cell-line models. MRPL30P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MRPL30P1 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, MRPL30P1 RNA expression shows 7,034 significant gene co-expression associations, with the highest sampling consensus in CHOL. Together, these results highlight MESO, UCEC, and CHOL as cancer lineages where MRPL30P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL30P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL30P1 survival associations across molecular data types. MRPL30P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL30P1 RNA expression–survival associations across cancer types. High MRPL30P1 expression shows unfavorable associations in MESO, ACC, UVM, SKCM and KICH, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MRPL30P1 RNA expression.
This table summarizes MRPL30P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL30P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL30P1 shows lower tumor expression in KICH and higher tumor expression in UCEC, HNSC, LUSC, COAD and LUAD. The UCEC box plot shows higher MRPL30P1 RNA expression in tumor versus normal tissue (log2 FC = +0.277, t-test p = .011).
This table shows molecular features associated with MRPL30P1 in patient tissues and cancer cell lines. In patient samples, MRPL30P1 shows the broadest associations at the RNA and protein expression levels, with CHOL recurring as the lineage with the largest associated feature set.
